Replies to post #207667 on Biotech Values

[DewDiligence]

MRTX +83%/AH—27% ORR(n=11)for Sitravatinib/Opdivo in PD-1 failures in NSCLC:

http://www.prnewswire.com/news-releases/mirati-therapeutics-presents-positive-preliminary-data-from-on-going-clinical-trials-of-sitravatinib-in-non-small-cell-lung-cancer-300520065.html